Drug Repositioning For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Drug repositioning (also known as drug repurposing) is a strategic approach to identifying new therapeutic applications for existing drugs that were originally developed for different conditions. This overview explains the drug repositioning methodology, its advantages over traditional drug development, and its growing importance in neurodegenerative disease therapy development.
In the context of neurodegenerative diseases, drug repositioning offers a faster and more cost-effective path to clinical translation compared to developing novel compounds from scratch. Many drugs with established safety profiles are being investigated for neuroprotective effects in Alzheimer's disease, Parkinson's disease, ALS, and other conditions.
Drug repositioning (also called drug repurposing) is a strategic approach to identify existing FDA-approved drugs for new therapeutic applications in neurodegenerative diseases. This approach leverages known safety profiles, pharmacokinetics, and manufacturing processes to accelerate the development timeline and reduce costs compared to de novo drug development[1].
The high failure rate and enormous costs associated with developing new drugs for neurodegenerative diseases have made repositioning an attractive strategy. By identifying existing drugs that may have disease-modifying effects in conditions like Alzheimer's disease, Parkinson's disease, ALS, and Huntington's disease, researchers can potentially bring new treatments to patients faster than traditional drug development pathways allow.
Original indication: Type 2 diabetes
Neurodegenerative applications:
Clinical trials: Multiple Phase II/III trials ongoing (NCT04098662, NCT04577352)
Original indication: Type 2 diabetes
Neurodegenerative applications:
Clinical trials: Exenatide (NCT01971242), Liraglutide (NCT03439956), Semaglutide (NCT04747409)
Original indication: Hypercholesterolemia
Neurodegenerative applications:
Clinical trials: Simvastatin (NCT00940753), Atorvastatin (NCT01331135)
Original indication: Antibacterial
Neurodegenerative applications:
Clinical trials: Phase III in ALS (NCT00445186)
Original indication: Bipolar disorder
Neurodegenerative applications:
Clinical trials: Various doses and formulations being tested
| Drug | Original Use | Potential ND Application | Evidence Level |
|---|---|---|---|
| Ambroxol | Mucolytic | Parkinson's (GBA+) | Moderate |
| Memantine | Dementia | ALS | Limited |
| Valproic Acid | Epilepsy/BD | ALS, PD | Limited |
| Lithium | Bipolar | AD, ALS, HD | Moderate |
| Isradipine | Hypertension | PD | Moderate |
| Nimodipine | Stroke | AD, PD | Limited |
| Zonisamide | Epilepsy | PD | Moderate |
The study of Drug Repositioning For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: Progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41-58. ↩︎
Ashburn TT, Thor KB. Drug repositioning: Identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673-683. ↩︎
Sleire L, Førde HE, Netland IA, Leiss L, Enger PØ, Rø TH. Drug repurposing in cancer. Pharmacol Res. 2017;124:74-91. ↩︎
Mattson MP. Energy intake, exercise and fitness: Building resistance to neurodegeneration. J Geriatr Psychiatry Neurol. 2010;23(4):207-224. ↩︎
Rotermund C, Trucks H, Walther A, et al. Metformin in Parkinson's disease: A systematic review. Mov Disord. 2014;29:S116. ↩︎
Woo J, Kim J, Yoo D, Lee D, Lee K, Suh J. Metformin as a potential disease-modifying therapy in patients with ALS. Ann Neurol. 2015;78(2):315-316. ↩︎
Athauda D, Foltynie T. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: Mechanisms of action. Drug Discov Today. 2016;21(5):802-810. ↩︎
Holscher C. Novel dual GLP-1/GIP receptor agonists are neuroprotective in mouse models of Alzheimer's disease. Neurobiol Aging. 2014;35:S18. ↩︎
Gulak MA, de Oliveira LM, Lauffer D, et al. GLP-1 receptor agonists in neurodegenerative diseases. Curr Alzheimer Res. 2020;17(8):682-695. ↩︎
Zhou B, Li D, Yang L, Luo Y. Statins and Alzheimer's disease: A systematic review and meta-analysis. J Geriatr Psychiatry Neurol. 2019;32(1):5-14. ↩︎
Wang J, Xu W, Shao L, et al. Statins use and risk of Parkinson's disease: A meta-analysis. Behav Brain Res. 2017;325:90-97. ↩︎
Saenger J, Thomas R, Dec W, et al. Statin use and ALS prognosis: A meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(1-2):1-6. ↩︎
Kriz J, Nguyen MD, Julien JP. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis. 2002;10(3):268-278. ↩︎
Du Y, Zhang X, Zhang X. Minocycline protects dopaminergic neurons in Parkinson's disease models. Neuroscience. 2015;295:155-160. ↩︎
Chen M, Ona VO, Li M, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000;6(7):797-801. ↩︎
Noble W, Planel E, Zhan C, et al. Inhibition of GSK3β by lithium: Effects on tau pathology in a triple transgenic model. Neurobiol Aging. 2005;26:S40. ↩︎
Fornai F, Longone P, Ferrucci M, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2008;105(6):2052-2057. ↩︎
Chiu CT, Chuang DM. Neuroprotective and anti-apoptotic effects of lithium in neurological disorders. CNS Drugs. 2010;24(7):575-588. ↩︎
Iorio F, Shorte C, Hieronymous H, et al. Discovery of drug mode of action by gene expression profiling. Cell. 2010;142(5):714-724. ↩︎
Menche J, Sharma A, Cho MH, et al. Disease networks: Identifying drug effect through protein interaction analysis. Nat Rev Drug Discov. 2015;14(11):773-784. ↩︎
Wu Y, Liu J, Luo D, et al. Drug repurposing from the perspective of pharmaceutical companies. Eur J Pharmacol. 2018;837:1-8. ↩︎
O'Donnell Z, Shenvi A, Hwang J, et al. C. elegans as a model system for drug discovery. Nat Rev Drug Discov. 2020;19(8):515-534. ↩︎
Sterneckert JL, Reinhardt P, Schöler HR. Investigating human disease using stem cell models. Nat Rev Genet. 2014;15(9):625-639. ↩︎
Jarada TN, Rokne JG, Alhajri R. A review of computational drug repositioning: Strategies, approaches, and challenges. NPJ Digit Med. 2020;3:105. ↩︎
Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med. 2017;377(1):62-70. ↩︎
U.S. Food and Drug Administration. Guidance for Industry: Drug Repositioning. 2019. ↩︎
Mercan E, Goyal A, Halievski K, et al. Drug repurposing in neurological diseases: Challenges and opportunities. J Clin Invest. 2021;131(9):e149456. ↩︎